To determine if transcript expression of relevant HhP genes correlated with single-agent activity or synergy, we assessed HhP signaling genes (e.g., SMO, SHH), HhP transcription factors (GLI-1, GLI-2, and GLI-3), and representative transcriptional target genes (e.g., anti-apoptotic BCL-2 and BCL-XL [BCL2L1] and CDK1) for their expression in the four AML cell lines used in RNAi screening experiments (TF-1, HEL, MDS-L, and THP-1), and enriched the dataset with an additional cell line (MV4-11) for which RNA sequencing (RNAseq) data and drug treatment data was available. The gene discussed is SMO; the disease is acute myeloid leukemia.